A D Santin

Summary

Affiliation: University of Arkansas for Medical Sciences
Country: USA

Publications

  1. ncbi Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy
    Alessandro D Santin
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Int J Cancer 112:14-25. 2004
  2. ncbi Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock 72205 7199, USA
    Gynecol Oncol 89:271-80. 2003
  3. ncbi Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy
    Alessandro D Santin
    Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA
    Curr Pharm Des 11:3485-500. 2005
  4. ncbi Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 7199, USA
    Clin Cancer Res 11:3320-5. 2005
  5. pmc Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
    A D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Br J Cancer 92:1561-73. 2005
  6. ncbi The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma
    Alessandro D Santin
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cancer 98:1898-904. 2003
  7. ncbi Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma
    Alessandro D Santin
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 7199, USA
    Cancer 104:1391-7. 2005
  8. ncbi Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy
    Alessandro D Santin
    Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Virology 331:269-91. 2005
  9. pmc Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling
    A D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, UAMS Medical Center, 4301 West Markham, Little Rock, AR 72205 7199, USA
    Br J Cancer 90:1814-24. 2004
  10. ncbi Current treatment options for endometrial cancer
    Alessandro D Santin
    University of Arkansas for Medical Sciences, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, 4301 West Markham Street, Slot 518, Little Rock, AR 72205, USA
    Expert Rev Anticancer Ther 4:679-89. 2004

Research Grants

  1. Dendritic Cell Immunotherapy for Cervical Cancer
    Alessandro Santin; Fiscal Year: 2004

Collaborators

Detail Information

Publications56

  1. ncbi Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy
    Alessandro D Santin
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Int J Cancer 112:14-25. 2004
    ..NOVA. These results, obtained with highly purified primary cultures of ovarian cancer, highlight important molecular features of OSPC and may provide a foundation for the development of new type-specific therapies against this disease...
  2. ncbi Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock 72205 7199, USA
    Gynecol Oncol 89:271-80. 2003
    ....
  3. ncbi Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy
    Alessandro D Santin
    Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA
    Curr Pharm Des 11:3485-500. 2005
    ....
  4. ncbi Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 7199, USA
    Clin Cancer Res 11:3320-5. 2005
    ..The discovery of novel biomarkers might greatly contribute to improve clinical management and outcomes in uterine serous papillary carcinoma (USPC), a highly aggressive variant of endometrial cancer...
  5. pmc Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
    A D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Br J Cancer 92:1561-73. 2005
    ..Our results highlight the novel molecular features of USPC and provide a foundation for the development of new type-specific therapies against this highly aggressive variant of endometrial cancer...
  6. ncbi The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma
    Alessandro D Santin
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cancer 98:1898-904. 2003
    ..To assess the value of TADG-15 as a possible marker for tumor detection and/or as a target for therapeutic intervention, the authors investigated the frequency of expression of TADG-15 in human cervical tumors...
  7. ncbi Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma
    Alessandro D Santin
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 7199, USA
    Cancer 104:1391-7. 2005
    ..In the current study, the authors have determined the frequency and clinical significance of HER-2/neu gene amplification in uterine serous papillary endometrial carcinoma (USPC), a highly aggressive variant of endometrial carcinoma...
  8. ncbi Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy
    Alessandro D Santin
    Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Virology 331:269-91. 2005
    ....
  9. pmc Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling
    A D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, UAMS Medical Center, 4301 West Markham, Little Rock, AR 72205 7199, USA
    Br J Cancer 90:1814-24. 2004
    ..A therapeutic strategy targeting HER-2/neu may be beneficial in patients harbouring chemotherapy-resistant USPC...
  10. ncbi Current treatment options for endometrial cancer
    Alessandro D Santin
    University of Arkansas for Medical Sciences, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, 4301 West Markham Street, Slot 518, Little Rock, AR 72205, USA
    Expert Rev Anticancer Ther 4:679-89. 2004
    ..Anti-HER-2/neu-targeted therapy might be a novel and attractive therapeutic strategy in patients harboring this biologically aggressive variant of endometrial cancer...
  11. ncbi The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in squamous cervical cancer cells
    Alessandro D Santin
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, UAMS Medical Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Gynecol Oncol 94:283-8. 2004
    ....
  12. ncbi HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, 4301 W Markham, Little Rock, AR 72205 7199, USA
    Gynecol Oncol 100:469-78. 2006
    ....
  13. ncbi Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Int J Radiat Oncol Biol Phys 54:1345-55. 2002
    ..To analyze prospectively the effects of blood transfusion administered during radiotherapy (RT) on the immune function of patients with locally advanced cervical cancer...
  14. ncbi Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE)
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Cancer 109:1312-22. 2007
    ..The potential for targeting this pathway in the treatment of USPC was explored...
  15. ncbi Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas
    Alessandro D Santin
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 7199, USA
    Clin Cancer Res 13:3339-46. 2007
    ....
  16. ncbi Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer
    A D Santin
    Department of Otolaryngology, University of Arkansas for Medical Sciences, USA
    Minerva Ginecol 54:133-44. 2002
    ..In this review, we describe these ovarian tumor antigens and assess the potential for therapeutic DC vaccination for the treatment of chemotherapy-resistant ovarian cancer...
  17. ncbi Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer
    Alessandro D Santin
    Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Am J Obstet Gynecol 192:813-8. 2005
    ....
  18. pmc Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer
    A D Santin
    Department of Obstetrics and Gynecology, UAMS Medical Center, Division of Gynecologic Oncology, University of Arkansas, 4301 W Markham, Little Rock, Arkansas AR 72205 7199, USA
    Br J Cancer 86:151-7. 2002
    ..These results may have important implications for the treatment in the adjuvant setting of uterine serous papillary cancer patients with active or adoptive immunotherapy...
  19. pmc Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial
    Alessandro D Santin
    UAMS Medical Center, Division of Gynecologic Oncology, University of Arkansas, 4301 W Markham, Little Rock, AR 72205 7199, USA
    J Virol 82:1968-79. 2008
    ..Phase II E7-pulsed DC-based vaccination trials with cervical cancer patients harboring a limited tumor burden, or who are at significant risk of tumor recurrence, are warranted...
  20. ncbi Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma
    A R Clemons-Miller
    Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    Clin Cancer Res 7:917s-924s. 2001
    ..There was no evidence of tumor progression throughout the treatment period, and clinically the patient showed some resolution of neurological symptoms...
  21. ncbi Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix
    A D Santin
    Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205-7199, USA
    Gynecol Oncol 81:424-32. 2001
    ..The recruitment and accumulation of high concentrations of antigen-experienced T lymphocytes in the cervical tumor tissue may represent an important local barrier to neoplastic dissemination...
  22. ncbi Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells
    A D Santin
    Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock 72205-7199, USA
    Clin Cancer Res 7:804s-810s. 2001
    ....
  23. ncbi Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer
    A D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205-7199, USA
    Gynecol Obstet Invest 51:254-61. 2001
    ....
  24. ncbi Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer
    A D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, UAMS Medical Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Int J Gynecol Cancer 14:64-75. 2004
    ..DC-stimulated TIL may represent a superior source of tumor-specific CTL for adoptive T-cell immunotherapy for advanced ovarian cancer...
  25. ncbi Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme
    Kristina L Bondurant
    Department of Microbiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Clin Cancer Res 11:3446-54. 2005
    ..In this study, we tested the hypothesis that dendritic cells loaded with SCCE peptides will induce ovarian tumor antigen-specific CD8+ CTL responses and antigen-specific CD4+ helper T cell responses...
  26. ncbi Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer
    A D Santin
    Department of Obstetrics and Gynaecology, University of Arkansas, Little Rock, USA
    BJOG 108:804-8. 2001
    ....
  27. ncbi Overexpression of HER-2/neu in uterine serous papillary cancer
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas, Little Rock 72205 7199, USA
    Clin Cancer Res 8:1271-9. 2002
    ..In this study, we have evaluated the expression of HER-2/neu in several fresh, established, paraffin-embedded, fixed USPCs. In addition, we have tested the sensitivity of USPC cells to Herceptin treatment...
  28. pmc Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas
    E Bignotti
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Brescia, Viale Europa 11, 25123 Brescia, Italy
    Br J Cancer 99:768-73. 2008
    ..Further investigations on a wider set of samples are warranted to validate TFF3 as a novel serum marker for early detection and/or monitoring of G3-EEC patients...
  29. ncbi Influence of allogeneic blood transfusion on clinical outcome during radiotherapy for cancer of the uterine cervix
    A D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205 7199, USA
    Gynecol Obstet Invest 56:28-34. 2003
    ..Prospective randomized studies are strongly warranted to confirm this hypothesis...
  30. ncbi The novel serine protease tumor-associated differentially expressed gene-14 (KLK8/Neuropsin/Ovasin) is highly overexpressed in cervical cancer
    Stefania Cane
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Am J Obstet Gynecol 190:60-6. 2004
    ..The goal of this study was to investigate the frequency of expression of the TADG-14 gene in human cervical tumors...
  31. doi Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Yale University School of Medicine, New Haven, Connecticut 06520 8063, USA
    Int J Gynaecol Obstet 102:128-31. 2008
    ..To study the effect of trastuzumab in patients with progressive or recurrent metastatic endometrial carcinoma shown by immunohistochemistry to overexpress the HER2/neu receptor...
  32. ncbi Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells
    Rena Kass
    Department of General Surgery, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Breast Cancer Res Treat 80:275-85. 2003
    ..These results may have important implications for the treatment of chemotherapy resistant breast cancer with active or adoptive immunotherapy...
  33. pmc Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas
    Chiara Romani
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Brescia, Brescia, Italy
    Am J Obstet Gynecol 201:70.e1-9. 2009
    ..The purpose of this study was to develop and characterize a human antibody in a single-chain antibody fragment format (scFv) that is directed specifically against claudin-3 (CLDN3)...
  34. ncbi Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 7199, USA
    Cancer Res 65:4334-42. 2005
    ..e., 4-week established OVA-1). Our findings suggest that CPE may have potential as a novel treatment for chemotherapy-resistant/recurrent ovarian cancer...
  35. ncbi Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease
    Stefania Bellone
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Gynecol Oncol 106:513-20. 2007
    ..To evaluate the sensitivity of cervical cancer cell lines to treatment with a chimeric MAb against EGFR-1 (Cetuximab)...
  36. ncbi Local administration of interleukin-11 ameliorates intestinal radiation injury in rats
    Marjan Boerma
    Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Cancer Res 67:9501-6. 2007
    ..These data show that local administration of rhIL-11 ameliorates early intestinal radiation injury and support further development of rhIL-11 to reduce manifestations of intestinal radiation injury in the clinic...
  37. ncbi Advances in dendritic-cell-based therapeutic vaccines for cervical cancer
    Stefania Bellone
    University of Arkansas for Medical Sciences, Department of Obstetrics and Gynecology, 4301 West Markham, Little Rock, AR 72205, USA
    Expert Rev Anticancer Ther 7:1473-86. 2007
    ....
  38. ncbi Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer
    Martin J Cannon
    Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA
    Expert Rev Anticancer Ther 2:97-105. 2002
    ..In this review, a series of recently identified novel ovarian tumor antigens is discussed, and the potential for therapeutic dendritic cell vaccination targeted against these antigens is assessed...
  39. ncbi Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor
    Mary Pat Hardman
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 7199, USA
    Obstet Gynecol 110:518-20. 2007
    ..Metastatic and disseminated uterine leiomyosarcoma has limited chemotherapeutic options...
  40. ncbi Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas
    Alessandro D Santin
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Am J Obstet Gynecol 194:1296-302. 2006
    ..The goal of this study was to investigate the expression and secretion levels in vitro and in vivo of kallikrein 10 in uterine serous papillary carcinoma, a highly aggressive variant of endometrial tumor...
  41. ncbi In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells
    Rena Kass
    Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    J Surg Res 112:189-97. 2003
    ..Dendritic cells (DCs) are the most powerful antigen-presenting cells, and recently DC-based vaccination has shown great promise for the treatment of human malignancies by immunological intervention...
  42. ncbi Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, 4301 W Markham Street, Slot 518, Little Rock, AR 72205 7199, USA
    Gynecol Oncol 98:24-30. 2005
    ..To evaluate and compare HER2/neu protein overexpression and gene amplification in uterine serous papillary endometrial cancer (USPC)...
  43. ncbi Immunological treatment of ovarian cancer
    Martin J Cannon
    Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Curr Opin Obstet Gynecol 16:87-92. 2004
    ..Several recent studies presented in this review, however, point to a revival of optimism for the development of novel immunotherapeutic strategies...
  44. ncbi Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy
    Stefania Bellone
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Gynecol Oncol 91:231-40. 2003
    ....
  45. ncbi High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer
    Stefania Bellone
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Gynecol Oncol 98:92-8. 2005
    ....
  46. ncbi Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone
    Kevin H Kim
    Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Cancer Immun 6:9. 2006
    ....
  47. ncbi The CA 125 gene: an extracellular superstructure dominated by repeat sequences
    T J O'Brien
    Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Tumour Biol 22:348-66. 2001
    ..Sequencing the gene provides us with the ability to initiate the quest to understand the biological function of CA 125...
  48. doi Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole
    Stefania Bellone
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology Yale University School of Medicine, New Haven, CT 06520 8063, USA
    Am J Obstet Gynecol 199:e7-e10. 2008
    ..We report the case of 58-year-old woman with recurrent endometrial carcinoma that was resistant to chemotherapy that was treated successfully with the aromatase inhibitor anastrozole...
  49. ncbi Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    BJOG 111:613-8. 2004
    ..To assess the expression of total gangliosides in primary ovarian cancer cell lines, ascitic fluid and plasma of advanced ovarian cancer patients...
  50. ncbi Low-grade fibromyxoid sarcoma presenting clinically as a primary ovarian neoplasm: a case report
    Harry L Winfield
    Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Int J Gynecol Pathol 26:173-6. 2007
    ..The patient has stable residual disease 11 months postoperatively. This case adds to the literature of intra-abdominal low-grade fibromyxoid sarcoma and expands the list of malignant mesenchymal neoplasms that may involve the ovary...
  51. ncbi Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer
    Alessandro D Santin
    N Engl J Med 346:1752-3. 2002
  52. ncbi Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes
    Eliana Bignotti
    Division of Gynecologic Oncology, University of Brescia Medical School, Brescia, Italy
    Am J Obstet Gynecol 196:245.e1-11. 2007
    ..The purpose of this study was to identify genes that are highly differentially expressed in metastatic serous papillary ovarian tumors (MET) when compared with primary ovarian serous carcinomas (OSPC)...
  53. ncbi Overexpression of mammaglobin B in epithelial ovarian carcinomas
    Renata A Tassi
    Division of Gynecologic Oncology, University of Brescia, Brescia, Italy
    Gynecol Oncol 105:578-85. 2007
    ..In order to evaluate its potential as a novel ovarian cancer biomarker, in this study we quantified and compared Mammaglobin B expression in various histologic types of epithelial ovarian carcinomas (EOC)...
  54. ncbi Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy
    Eliana Bignotti
    Division of Gynecologic Oncology, University of Brescia, Brescia, Italy
    Gynecol Oncol 103:405-16. 2006
    ..To compare the genetic fingerprints of flash-frozen ovarian serous carcinomas to those of matched highly purified primary tumor cell cultures...
  55. ncbi HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed?
    Alessandro D Santin
    Gynecol Oncol 88:263-5. 2003
  56. ncbi Immunogenic gangliosides in human ovarian carcinoma
    Mepur H Ravindranath
    Laboratory of Glycoimmunotherapy, John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Boulevard, Santa Monica, CA 90404 2302, USA
    Biochem Biophys Res Commun 353:251-8. 2007
    ..The significance of the endogenous IgM response to GD1a may be to eliminate this immunosuppressive-ganglioside from the tumor-microenvironment...

Research Grants2

  1. Dendritic Cell Immunotherapy for Cervical Cancer
    Alessandro Santin; Fiscal Year: 2004
    ..This study will determine whether E7 antigen-loaded autologous DC vaccination offers the potential of therapeutic benefit for patients with HPV16 or HPV18-associated cervical cancer. ..